Hodgkin lymphoma (HL) comprises two distinct diseases: the classical Hodgkin lymphoma and the much less frequently occuring nodular lymphocyte-predominant Hodgkin lymphoma. The classical HL has bimodal pattern of incidence with peaks in young adults and elderly patients. Treatment of HL consists of chemotherapy and radiotherapy. Currently can be cured more than 80 % of patients. One very important issue in the present management of HL is how to minimize toxic side effects of treatment, especially late toxicity. There is also need of new therapeutic approaches for patients with chemorefractory disease and for the group of patients with numerous adverse prognostic factors, which have relatively small chance of cure with currently available therapies.